Impact of plasmapheresis on severe COVID-19
Gandhy Thomas Fonseca-González, Mario Eduardo Alamilla Sanchez, Vanessa García-Macas, José Herrera-Acevedo, Mauricio Villalobos-Brito, Édgar Tapia-Rangel, Diana Maldonado-Tapia, Mónica López-Mendoza, José Horacio Cano-Cervantes, Julita Orozco-Vázquez, David E. Timaran, Silvia Cortés-Martínez, Maricela Escarela-Serrano, Sandra Muñoz-López, Luis Montiel-López, Paul Mondragón‐Terán, Juan Antonio Suárez‐Cuenca
Abstract
Abstract The clinical course of COVID-19 may show severe presentation, potentially involving dynamic cytokine storms and T cell lymphopenia, which are leading causes of death in patients with SARS-CoV-2 infection. Plasma exchange therapy (PLEX) effectively removes pro-inflammatory factors, modulating and restoring innate and adaptive immune responses. This clinical trial aimed to evaluate the impact of PLEX on the survival of patients with severe SARS-CoV-2 and the effect on the cytokine release syndrome. Hospitalized patients diagnosed with SARS-CoV-2 infection and cytokine storm syndrome were selected to receive 2 sessions of PLEX or standard therapy. Primary outcome was all-cause 60-days mortality; secondary outcome was requirement of mechanical ventilation, SOFA, NEWs-2 scores modification, reduction of pro-inflammatory biomarkers and hospitalization time. Twenty patients received PLEX were compared against 40 patients receiving standard therapy. PLEX reduced 60-days mortality (50% vs 20%; OR 0.25, 95%CI 0.071–0.880; p = 0.029), and this effect was independent from demographic variables and drug therapies used. PLEX significantly decreased SOFA, NEWs-2, pro-inflammatory mediators and increased lymphocyte count, accompanied with a trend to reduce affected lung volume, without effect on SatO 2 /FiO 2 indicator or mechanical ventilation requirement. PLEX therapy provided significant benefits of pro-inflammatory clearance and reduction of 60-days mortality in selected patients with COVID-19, without significant adverse events.